Impact of atorvastatin on serum vaspin levels in hypercholesterolemic patients with moderate cardiovascular risk

Regulatory Peptides

Volumn 170, Issue 1-3, 2011, Pages 57-61

  Kadoglou, Nikolaos P E ^a,b   Vrabas, Ioannis S ^a   Kapelouzou, Alkistis ^c   Lampropoulos, Stylianos ^d   Sailer, Nikolaos ^b   Kostakis, Alkiviadis ^c   Liapis, Christos D ^e  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b Aristotle University of Thessaloniki   (Greece)

^c BIOMEDICAL RESEARCH FOUNDATION   (Greece)

^d Department of Cardiology   (Greece)

^e UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Adipokines; Atorvastatin; Hypercholesterolemia; Lifestyle; Vaspin; Visfatin

Indexed keywords

ADIPOCYTOKINE; ATORVASTATIN; GLUCOSE; INSULIN; LIPID; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; VASPIN;

ADULT; ARTICLE; BLOOD SAMPLING; CARDIOVASCULAR RISK; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERCHOLESTEROLEMIA; INSULIN BLOOD LEVEL; LIFESTYLE MODIFICATION; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TREATMENT OUTCOME;

AGED; ANTICHOLESTEREMIC AGENTS; CORONARY ARTERY DISEASE; CYTOKINES; FEMALE; HEPTANOIC ACIDS; HUMANS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PROSPECTIVE STUDIES; PYRROLES; REGRESSION ANALYSIS; RISK FACTORS; RISK REDUCTION BEHAVIOR; SERPINS;

EID: 79959716190     PISSN: 01670115     EISSN: 18731686     Source Type: Journal    
DOI: 10.1016/j.regpep.2011.05.008     Document Type: Article

References (37)

1. Blüher M. Adipose tissue dysfunction in obesity. Exp Clin Endocrinol Diabetes 2009, 117:241-250.
2. Ronti T., Lupattelli G., Mannarino E. The endocrine function of adipose tissue: an update. Clin Endocrinol (Oxf) 2006, 64:355-365.
3. Kershaw E.E., Flier J.S. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004, 89:2548-2556.
4. Wada J. Vaspin: a novel serpin with insulin-sensitizing effects. Expert Opin Investig Drugs 2008, 17:327-333.
5. Hida K., Wada J., Eguchi J., Zhang H., Baba M., Seida A., Hashimoto I., Okada T., Yasuhara A., Nakatsuka A., Shikata K., Hourai S., Futami J., Watanabe E., Matsuki Y., Hiramatsu R., Akagi S., Makino H., Kanwar Y.S. Visceral adipose tissue-derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity. Proc Natl Acad Sci U S A 2005, 102:10610-10615.
6. Klöting N., Berndt J., Kralisch S., Kovacs P., Fasshauer M., Schön M.R., Stumvoll M., Blüher M. Vaspin gene expression in human adipose tissue: association with obesity and type 2 diabetes. Biochem Biophys Res Commun 2006, 339:430-436.
7. Youn B.S., Klöting N., Kratzsch J., Lee N., Park J.W., Song E.S., Ruschke K., Oberbach A., Fasshauer M., Stumvoll M., Blüher M. Serum vaspin concentrations in human obesity and type 2 diabetes. Diabetes 2008, 57:372-377.
8. Aust G., Richter O., Rohm S., Kerner C., Hauss J., Klöting N., Ruschke K., Kovacs P., Youn B.S., Blüher M. Vaspin serum concentrations in patients with carotid stenosis. Atherosclerosis 2009, 204:262-266.
9. Fukuhara A., Matsuda M., Nishizawa M., Segawa K., Tanaka M., Kishimoto K., Matsuki Y., Murakami M., Ichisaka T., Murakami H., Watanabe E., Takagi T., Akiyoshi M., Ohtsubo T., Kihara S., Yamashita S., Makishima M., Funahashi T., Yamanaka S., Hiramatsu R., Matsuzawa Y., Shimomura I. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 2005, 307:426-430.
10. Kadoglou N.P., Tsanikidis H., Kapelouzou A., Vrabas I., Vitta I., Karayannacos P.E., Liapis C.D., Sailer N. Effects of rosiglitazone and metformin treatment on apelin, visfatin, and ghrelin levels in patients with type 2 diabetes mellitus. Metabolism 2010, 59:373-379.
11. Kadoglou N.P.E., Sailer N., Moumtzouoglou A., Kapelouzou A., Tsanikidis H., Vitta I., Karkos C., Karayannacos P.E., Gerasimidis T., Liapis C.D. Novel markers of carotid atherosclerosis in patients with type 2 diabetes. Exp Clin Endocrinol Diabetes 2010, 118:75-80.
12. Kostapanos M.S., Derdemezis C.S., Filippatos T.D., Milionis H.J., Kiortsis D.N., Tselepis A.D., Elisaf M.S. Effect of rosuvastatin treatment on plasma visfatin levels in patients with primary hyperlipidemia. Eur J Pharmacol 2008, 14:249-252.
13. Derdemezis C., Filippatos T., Tselepis A., Mikhailidis D., Elisaf M. Effects of ezetimibe, either alone or in combination with atorvastatin, on serum visfatin levels: a pilot study. Expert Opin Pharmacother 2008, 9:1829-1837.
14. Kent S.M., Coyle L.C., Flaherty P.J., Markwood T.T., Taylor A.J. Marked low-density lipoprotein cholesterol reduction below current national cholesterol education program targets provides the greatest reduction in carotid atherosclerosis. Clin Cardiol 2004, 27:17-21.
15. Athyros V.G., Kakafika A.I., Tziomalos K., Karagiannis A., Mikhailidis D.P. Pleiotropic effects of statins-clinical evidence. Curr Pharm Des 2009, 15:479-489.
16. Redberg R.F., Benjamin E.J., Bittner V., Braun L.T., Goff D.C., Havas S., Labarthe D.R., Limacher M.C., Lloyd-Jones D.M., Mora S., Pearson T.A., Radford M.J., Smetana G.W., Spertus J.A., Swegler E.W. ACCF/AHA 2009 performance measures for primary prevention of cardiovascular disease in adults: a report of the American College of Cardiology Foundation/American Heart Association task force on performance measures (writing committee to develop performance measures for primary prevention of cardiovascular disease). Circulation 2009, 120:1296-1336.
17. National Cholesterol Education Program (NCEP) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III), third report of the National Cholesterol Education Program (NCEP). Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 2002, 106:3143-3421.
18. Kadoglou N.P., Kapelouzou A., Tsanikidis H., Vitta I., Liapis C.D., Sailer N. Effects of rosiglitazone/metformin fixed-dose combination therapy and metformin monotherapy on serum vaspin, adiponectin and IL-6 levels in drug-naïve patients with type 2 diabetes. Exp Clin Endocrinol Diabetes 2011, 119:63-68.
19. Derosa G., Maffioli P., Salvadeo S.A., Ferrari I., Gravina A., Mereu R., Palumbo I., Fogari E., D'Angelo A., Cicero A.F. Differential effects of candesartan and olmesartan on adipose tissue activity biomarkers in type II diabetic hypertensive patients. Hypertens Res 2010, 33:790-795.
20. Sailer G., Maffioli P., Ferrari I., Palumbo I., Randazzo S., D'Angelo A., Cicero A.F. Variation of inflammatory parameters after sibutramine treatment compared to placebo in type 2 diabetic patients. J Clin Pharm Ther 2010, [Epub ahead of print].
21. Oberbach A., Kirsch K., Lehmann S., Schlichting N., Fasshauer M., Zarse K., Stumvoll M., Ristow M., Blüher M., Kovacs P. Serum vaspin concentrations are decreased after exercise-induced oxidative stress. Obes Facts 2010, 3:328-331.
22. Körner A., Neef M., Friebe D., Erbs S., Kratzsch J., Dittrich K., Blüher S., Kapellen T.M., Kovacs P., Stumvoll M., Blüher M., Kiess W. Vaspin is related to gender, puberty and deteriorating insulin sensitivity in children. Int J Obes (Lond) 2011, 35:578-586.
23. El-Mesallamy H.O., Kassem D.H., El-Demerdash E., Amin A.I. Vaspin and visfatin/Nampt are interesting interrelated adipokines playing a role in the pathogenesis of type 2 diabetes mellitus. Metabolism 2011, 60:63-70.
24. Gulcelik N.E., Usman A., Gürlek A. Role of adipocytokines in predicting the development of diabetes and its late complications. Endocrine 2009, 36:397-403.
25. Wang Z., Nakayama T. Inflammation, a link between obesity and cardiovascular disease. Mediators Inflamm 2010, 2010:535-918.
26. Auguet T., Quintero Y., Riesco D., Morancho B., Terra X., Crescenti A., Broch M., Aguilar C., Olona M., Porras J.A., Hernandez M., Sabench F., Del Castillo D., Richart C. New adipokines vaspin and omentin. Circulating levels and gene expression in adipose tissue from morbidly obese women. BMC Med Genet 2011, 12:60.
27. Ozgen M., Koca S.S., Dagli N., Balin M., Ustundag B., Isik A. Serum adiponectin and vaspin levels in rheumatoid arthritis. Arch Med Res 2010, 41:457-463.
28. Fu B.D., Yamawaki H., Okada M., Hara Y. Vaspin can not inhibit TNF-alpha-induced inflammation of human umbilical vein endothelial cells. J Vet Med Sci 2009, 71:1201-1207.
29. Kim SM, Cho GJ, Yannakoulia M, Hwang TG, Kim IH, Park EK, Mantzoros CS. Lifestyle modification increases circulating adiponectin concentrations but does not change vaspin concentrations. Metabolism 2011. [Epub ahead of print].
30. Kadoglou N.P.E., Gkontopoulos A., Kapelouzou A., Fotiadis G., Theofilogiannakos E.K., Kottas G., Lampropoulos S. Serum levels of vaspin and visfatin in patients with coronary artery disease-Kozani study. Clin Chim Acta 2011, 412:48-52.
31. Mihos C.G., Salas M.J., Santana O. The pleiotropic effects of the hydroxy-methyl-glutaryl-CoA reductase inhibitors in cardiovascular disease: a comprehensive review. Cardiol Rev 2010, 18:298-304.
32. Pfützner A., Hanefeld M., Lübben G., Weber M.M., Karagiannis E., Köhler C., Hohberg C., Forst T. Visfatin: a putative biomarker for metabolic syndrome is not influenced by pioglitazone or simvastatin treatment in nondiabetic patients at cardiovascular risk-results from the PIOSTAT study. Horm Metab Res 2007, 39:764-768.
33. Liu S.W., Qiao S.B., Yuan J.S., Liu D.Q. Association of plasma visfatin levels with inflammation, atherosclerosis and acute coronary syndromes (ACS) in humans. Clin Endocrinol (Oxf) 2009, 71:202-207.
34. Dahl T.B., Yndestad A., Skjelland M., Øie E., Dahl A., Michelsen A., Damås J.K., Tunheim S.H., Ueland T., Smith C., Bendz B., Tonstad S., Gullestad L., Frøland S.S., Krohg-Sørensen K., Russell D., Aukrust P., Halvorsen B. Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: possible role in inflammation and plaque destabilization. Circulation 2007, 115:972-980.
35. Moschen A.R., Kaser A., Enrich B., Mosheimer B., Theurl M., Niederegger H., Tilg H. Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol 2007, 178:1748-1758.
36. Agueda M, Lasa A, Simon E, Ares R, Larrarte E, Labayen I. Association of circulating visfatin concentrations with insulin resistance and low-grade inflammation after dietary energy restriction in Spanish obese non-diabetic women: role of body composition changes. Nutr Metab Cardiovasc Dis 2010. [Epub ahead of print].
37. Chang H.M., Lee H.J., Park H.S., Kang J.H., Kim K.S., Song Y.S., Jang Y.J. Effects of weight reduction on serum vaspin concentrations in obese subjects: modification by insulin resistance. Obesity (Silver Spring) 2010, 18:2105-2110.